Outcome of AGM
Panacea Biotec Ltd has informed BSE that the 32nd Annual General Meeting (AGM) of the Company was held on September 28, 2016.29-09-2016
29-09-2016
Panacea Biotec Ensures limited availability of Life Saving Drug Cilamin 250 Capsule (D- Penicillamine IP 250 mg)
Panacea Biotec Ltd has informed BSE regarding a Press Release dated September 28, 2016 titled "Panacea Biotec Ensures limited availability of Life Saving Drug Cilamin 250 Capsule (D- Penicillamine IP 250 mg)".29-09-2016
Newspaper clips of Notice of Annual General Meeting and Remote E-voting
Panacea Biotec Ltd has submitted to BSE a copy of Newspaper clips of Notice of Annual General Meeting and Remote E-voting.23-09-2016
AGM on September 28, 2016
Panacea Biotec Ltd has informed BSE that the 32nd Annual General Meeting (AGM) of the Company will be held on September 28, 2016.07-09-2016
Fixes Book Closure for AGM
Panacea Biotec Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 24, 2016 to September 28, 2016 (both days inclusive) for the purpose of 32nd Annual General Meeting (AGM) of the Company to be held on September 28, 2016.13-08-2016
Standalone Financial Results, Limited Review Report for June 30, 2016
Panacea Biotec Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 20162. Standalone Limited Review for the period ended June 30, 201612-08-2016
Credit Rating
Panacea Biotec Ltd has informed BSE regarding "Credit Rating for Long Term Bank Facilities of Rs.959.55 cr. and Short Term Bank Facilities of Rs. 61.97 cr."02-08-2016
Board Meeting Intimation for Results & Closure of Trading Window
Panacea Biotec Ltd has informed BSE that a Meeting of the Board of Directors of the Company is scheduled to be held on August 12, 2016, inter alia, to consider and approve the Unaudited Financial Results (Provisional) for the quarter ended June 30, 2016.Further, pursuant to the provisions of Regulations 30 & 51 of the SEBI (LODR) Regulations, the trading window of the Company shall remain closed for all designated persons including promoters,...28-07-2016
Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
Sunanda Jain has submitted to BSE, vide letter dated July 27, 2016, a copy of disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a) (i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.27-07-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Panacea Biotec Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.21-07-2016